arrow
J

Joel R. Eisner

genecentric therapeutics inc.
H指数:19
被引数:2,025

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

一项关于口服lisavanbulin的剂量探索研究(1/2a期)及其生物标志物评估,用于治疗高级别胶质瘤或胶质母细胞瘤患者

2025-06-170
OA
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience (vol 125, pg 1251, 2021)
2022-03-112
OA
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience

转移性尿路上皮癌中成纤维细胞生长因子受体3的改变和对免疫检查点抑制的反应: 真实世界的经验

2021-07-22109
OAAI
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
2020-10-0221
OAAI
Repurposing antiandrogens to overcome therapy resistance in androgen receptor-positive glioblastoma
2020-08-150
PRE
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
2020-02-1128
OAAI